Clinical resources for healthcare providers
Find clinical resources to support your gastroparesis patients and practice.
Screening and referral
Patient screening & referral form
File type: PDF
Complete this form to screen your patient for gastroparesis and refer them for a GES therapy consultation.
Expand your options brochure
File type: PDF
An overview of Enterra Therapy, its indications, how the therapy works, and which patients may benefit.
Prior authorization request form
File type: PDF
Use this form to submit prior authorization requests for Enterra Therapy.
Coverage and coding
Coverage & coding information
File type: PDF
Information on reimbursement coding for GES.
Practice guidelines
AGA best practices review (2021)
“GES does improve refractory nausea and vomiting in some patients with gastroparesis and may improve glycemic control, nutritional status, and quality of life, while reducing hospitalizations and medication use.”1
ACG practice guidelines (2013)
“Conditional recommendation, moderate level of evidence, may be considered for compassionate use in patients with refractory symptoms, particularly nausea and vomiting.”2
- Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review [published online ahead of print, 2021 Oct 29]. Clin Gastroenterol Hepatol. 2021;S1542 3565(21)01151 4. doi:10.1016/j.cgh.2021.10.038.
- Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18-37.
MKT-D-0006, Rev E
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?